Alpha interferon in T helper phenotype chronic lymphocytic leukemia: a report of three cases

J Biol Regul Homeost Agents. 1988 Jan-Mar;2(1):31-4.

Abstract

Three patients affected by T helper chronic lymphocytic leukemia were treated with low dose interferon alpha-2b (3 MU/m2 3 times weekly). The disease presented different pathologic expressions with diffuse skin lesions in one patient, a mild clinical course and a prolymphocytic variant with aggressive features, respectively, in the other two cases. A consistent response was observed within 3-6 weeks; by that time a reduction of blood and marrow lymphocytosis in the three patients and a regression of the cutaneous lesions were documented. Therefore, it should be emphasized that the use of alpha IFN, whose effectiveness on cutaneous T cell lymphomas has been already demonstrated, may represent an active agent in the treatment of leukemic T helper phenotype chronic lymphocytic proliferations.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Female
  • HTLV-I Antibodies / analysis
  • Humans
  • Interferon Type I / pharmacology*
  • Leukemia, Prolymphocytic, T-Cell / therapy*
  • Male
  • Middle Aged
  • Phenotype
  • Recombinant Proteins
  • T-Lymphocytes, Helper-Inducer / immunology*

Substances

  • HTLV-I Antibodies
  • Interferon Type I
  • Recombinant Proteins